Johnson & Johnson (JNJ)
160.26
+1.74
(+1.10%)
USD |
NYSE |
Jun 08, 16:00
160.00
-0.26
(-0.16%)
Pre-Market: 04:56
Johnson & Johnson Revenue (TTM): 96.26B for March 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2023 | 96.26B |
| December 31, 2022 | 94.94B |
| September 30, 2022 | 96.04B |
| June 30, 2022 | 95.59B |
| March 31, 2022 | 94.88B |
| December 31, 2021 | 93.78B |
| September 30, 2021 | 91.45B |
| June 30, 2021 | 89.19B |
| March 31, 2021 | 84.21B |
| December 31, 2020 | 82.58B |
| September 30, 2020 | 80.86B |
| June 30, 2020 | 80.50B |
| March 31, 2020 | 82.73B |
| December 31, 2019 | 82.06B |
| September 30, 2019 | 81.71B |
| June 30, 2019 | 81.32B |
| March 31, 2019 | 81.59B |
| December 31, 2018 | 81.58B |
| September 30, 2018 | 81.38B |
| June 30, 2018 | 80.68B |
| March 31, 2018 | 78.69B |
| December 31, 2017 | 76.45B |
| September 30, 2017 | 74.36B |
| June 30, 2017 | 72.53B |
| March 31, 2017 | 72.17B |
| Date | Value |
|---|---|
| December 31, 2016 | 71.89B |
| September 30, 2016 | 71.60B |
| June 30, 2016 | 70.88B |
| March 31, 2016 | 70.18B |
| December 31, 2015 | 70.07B |
| September 30, 2015 | 70.52B |
| June 30, 2015 | 71.88B |
| March 31, 2015 | 73.59B |
| December 31, 2014 | 74.33B |
| September 30, 2014 | 74.43B |
| June 30, 2014 | 73.54B |
| March 31, 2014 | 71.92B |
| December 31, 2013 | 71.31B |
| September 30, 2013 | 70.52B |
| June 30, 2013 | 69.99B |
| March 31, 2013 | 68.59B |
| December 31, 2012 | 67.22B |
| September 30, 2012 | 65.92B |
| June 30, 2012 | 64.87B |
| March 31, 2012 | 65.00B |
| December 31, 2011 | 65.03B |
| September 30, 2011 | 64.42B |
| June 30, 2011 | 63.40B |
| March 31, 2011 | 62.13B |
| December 31, 2010 | 61.59B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
80.50B
Minimum
Jun 2020
96.26B
Maximum
Mar 2023
86.67B
Average
82.66B
Median
Revenue (TTM) Benchmarks
| Amgen Inc | 26.19B |
| Gilead Sciences Inc | 27.04B |
| Eli Lilly and Co | 27.69B |
| Merck & Co Inc | 57.87B |
| Moderna Inc | 14.77B |